Head-to-head evidence
MW02 vs RGX-314
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Age-Related Macular Degeneration
Shared mechanism: VEGF-A · full Age-Related Macular Degeneration pipeline
MW02
Developed by Mabwell (Shanghai) Bioscience Co., Ltd.
NCT05297292 · Phase 2/3 · status unknown
This is a randomized, quadruple-blind, active-controlled Phase 2/3 trial with a clinically meaningful primary endpoint (change in visual acuity), but no results have been posted yet, so the treatment effect versus the active comparator is still unknown.
RGX-314
Developed by REGENXBIO Inc.
NCT04832724 · Phase 2 · completed
The study enrolled 60 participants into sequential RGX-314 dose and formulation groups without randomization, blinding, or a comparator arm. Its primary endpoint was the surrogate pharmacodynamic measure of RGX-314 protein concentration, and no primary outcome results are available.
Next expected readout: December 2026 · NCT04704921 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: MW02's landscape · RGX-314's landscape